Literature DB >> 15005958

Gaussian process modeling in conjunction with individual patient simulation modeling: a case study describing the calculation of cost-effectiveness ratios for the treatment of established osteoporosis.

M D Stevenson1, J Oakley, J B Chilcott.   

Abstract

Individual patient-level models can simulate more complex disease processes than cohort-based approaches. However, large numbers of patients need to be simulated to reduce 1st-order uncertainty, increasing the computational time required and often resulting in the inability to perform extensive sensitivity analyses. A solution, employing Gaussian process techniques, is presented using a case study, evaluating the cost-effectiveness of a sample of treatments for established osteoporosis. The Gaussian process model accurately formulated a statistical relationship between the inputs to the individual patient model and its outputs. This model reduced the time required for future runs from 150 min to virtually-instantaneous, allowing probabilistic sensitivity analyses-to be undertaken. This reduction in computational time was achieved with minimal loss in accuracy. The authors believe that this case study demonstrates the value of this technique in handling 1st- and 2nd-order uncertainty in the context of health economic modeling, particularly when more widely used techniques are computationally expensive or are unable to accurately model patient histories.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15005958     DOI: 10.1177/0272989X03261561

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  17 in total

1.  Incorporation of uncertainty in health economic modelling studies.

Authors:  Anthony O'Hagan; Christopher McCabe; Ron Akehurst; Alan Brennan; Andrew Briggs; Karl Claxton; Elisabeth Fenwick; Dennis Fryback; Mark Sculpher; David Spiegelhalter; Andrew Willan
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 2.  Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature.

Authors:  Rachael L Fleurence; Cynthia P Iglesias; David J Torgerson
Journal:  Osteoporos Int       Date:  2005-06-25       Impact factor: 4.507

3.  Exploring uncertainty in cost-effectiveness analysis.

Authors:  Karl Claxton
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

4.  Evaluating Parameter Uncertainty in a Simulation Model of Cancer Using Emulators.

Authors:  Tiago M de Carvalho; Eveline A M Heijnsdijk; Luc Coffeng; Harry J de Koning
Journal:  Med Decis Making       Date:  2019-06-10       Impact factor: 2.583

5.  Continuous time simulation and discretized models for cost-effectiveness analysis.

Authors:  Marta O Soares; Luísa Canto E Castro
Journal:  Pharmacoeconomics       Date:  2012-12-01       Impact factor: 4.981

6.  Modelling the cost effectiveness of interventions for osteoporosis: issues to consider.

Authors:  Matt D Stevenson; Peter L Selby
Journal:  Pharmacoeconomics       Date:  2014-08       Impact factor: 4.981

7.  Some Health States Are Better Than Others: Using Health State Rank Order to Improve Probabilistic Analyses.

Authors:  Jeremy D Goldhaber-Fiebert; Hawre J Jalal
Journal:  Med Decis Making       Date:  2015-09-16       Impact factor: 2.583

Review 8.  Systematic review of the use of computer simulation modeling of patient flow in surgical care.

Authors:  Boris G Sobolev; Victor Sanchez; Christos Vasilakis
Journal:  J Med Syst       Date:  2009-07-07       Impact factor: 4.460

9.  Multiobjective Calibration of Disease Simulation Models Using Gaussian Processes.

Authors:  Aditya Sai; Carolina Vivas-Valencia; Thomas F Imperiale; Nan Kong
Journal:  Med Decis Making       Date:  2019-08-02       Impact factor: 2.583

10.  Linear regression metamodeling as a tool to summarize and present simulation model results.

Authors:  Hawre Jalal; Bryan Dowd; François Sainfort; Karen M Kuntz
Journal:  Med Decis Making       Date:  2013-06-27       Impact factor: 2.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.